Biocept (BIOC) versus IRIS International (IRIS) Financial Review

IRIS International (NASDAQ: IRIS) and Biocept (NASDAQ:BIOC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, dividends and risk.

Valuation and Earnings

This table compares IRIS International and Biocept’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IRIS International N/A N/A N/A $0.04 201.25
Biocept $3.22 million 10.81 -$18.39 million ($0.89) -1.29

IRIS International has higher earnings, but lower revenue than Biocept. Biocept is trading at a lower price-to-earnings ratio than IRIS International, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IRIS International and Biocept’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IRIS International -61.58% -36.70% -29.47%
Biocept -375.28% -359.21% -157.08%

Volatility and Risk

IRIS International has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Biocept has a beta of 2.77, meaning that its stock price is 177% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for IRIS International and Biocept, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IRIS International 0 0 0 0 N/A
Biocept 0 0 3 0 3.00

Biocept has a consensus target price of $2.25, indicating a potential upside of 95.65%. Given Biocept’s higher possible upside, analysts plainly believe Biocept is more favorable than IRIS International.

Insider & Institutional Ownership

68.9% of IRIS International shares are owned by institutional investors. Comparatively, 8.0% of Biocept shares are owned by institutional investors. 9.7% of IRIS International shares are owned by insiders. Comparatively, 7.7% of Biocept shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

IRIS International beats Biocept on 6 of the 10 factors compared between the two stocks.

IRIS International Company Profile

Mitcham Industries, Inc. is a provider of equipment to the geophysical, oceanographic and hydrographic industries. The Company operates through two segments. The Equipment Leasing segment is primarily engaged in the leasing of seismic equipment to companies in the oil and gas industry across the world. The Equipment Manufacturing and Sales segment is engaged in the design, production and sale of marine seismic equipment, and oceanographic and hydrographic equipment. Its leasing business includes Mitcham Canada ULC, Seismic Asia Pacific Pty Ltd., Mitcham Seismic Eurasia LLC, Mitcham Europe Ltd. and Mitcham Marine Leasing Pte. Ltd. The Equipment Manufacturing and Sales Segment includes its Seamap International Holdings Pte, Ltd. (Seamap) business and Klein Marine Systems, Inc. (Klein). Seamap designs, manufactures and sells a range of products for the seismic, hydrographic and offshore industries. Klein develops and manufactures high performance side scan sonar systems.

Biocept Company Profile

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

Receive News & Ratings for IRIS International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIS International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply